Undiagnosed IgG4 Related DiseasesNCT02229448
Retrospective Study for Diagnosis of Undetected IgG4 Related Diseases in Patients With High Serum IgG4 Levels.
An observational study of Undiagnosed IgG4 Related Diseases, run by Meir Medical Center at 1 site in Israel.
Trial summary
Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology comprised of a collection of disorders that share specific pathologic, serologic, and clinical features. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Undiagnosed IgG4 Related Diseases
- How many people
- 11 participants
- Where
- 1 siteIsrael
- Study dates
- Oct 2014to Sep 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients that where admitted during the period of January 2000 to June 2014 at MEIR HOSPITAL- KFAR SABA from all ages, from all parts of Israel, all races will be included, from both genders.
Who may be able to join
- All patients that where admitted during the period of January 2000 to June 2014 at MEIR HOSPITAL KFAR SAVA, with at least one result of a high serum level of IGG4 according to the accepted normal range in our laboratory (more than 100mg/dL) and to whom biopsy of a suitable tissue was obtained for other reasons than IGG4 Related Diseases.
- Both genders will be included.
- Patients of all ages.
Who cannot join
- Patients who have already been diagnosed with IGG4-Related Diseases.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Survey of Patients With Elevated Serum IGG4 With Unknown IGG4-related Disease to Whom Biopsy and Performance of Subsequent Specific Staining for Clinical, Laboratory and Pathologic Correlation.
Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology comprised of a collection of disorders that share specific pathologic, serologic, and clinical features.
Histopathological analysis of biopsy specimens remains the cornerstone in the diagnosis of IgG4- related disease. Elevated concentrations of IgG4 in tissue and serum are helpful in diagnosing IgG4-related disease, but neither one is a specific diagnostic marker. Correlation with specific histopathological findings is essential, regardless of the serum IgG4 concentration, the number of IgG4-positive plasma cells in tissue, or the ratio of IgG4 to IgG in tissue. Misdiagnoses of IgG4-related disease are increasingly common because of excessive emphasis on moderate elevations of serum IgG4 concentration and overreliance on the finding of IgG4-positive plasma cells in tissue.
Read the detailed description
IgG4 is a unique antibody in both structure and function. This molecule accounts for less than 5% of the total IgG in healthy persons and is the least abundant IgG subclass. In contrast to IgG1, IgG2, and IgG3, serum IgG4 concentrations among ostensibly healthy people vary by a factor of more than 100 (normal range, 0.01 to 1.4 mg per milliliter), but IgG4 concentrations within individual persons are generally stable.
Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology comprised of a collection of disorders that share specific pathologic, serologic, and clinical features.
These different conditions were previously thought to be unrelated [2-4]. The commonly shared features include tumor-like swelling of involved organs, a lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells, and variable degrees of fibrosis that has a characteristic "storiform" pattern. In addition, elevated serum concentrations of IgG4 are found in 60 to 70 percent of patients with IgG4-RD.
Two major presentations of this condition, which often affects more than one organ, are type 1 autoimmune pancreatitis (IgG4-related pancreatitis) and salivary gland disease; the later may present as salivary gland enlargement or as sclerosing sialadenitis (formerly termed "Mikulicz disease" and Küttner's tumor, respectively). These conditions often resemble Sjögren's syndrome but are pathophysiologically distinct from this disorder. The preferred name for the overall condition is IgG4-related disease.
The presence of IgG4-bearing plasma cells is required for a diagnosis of IgG4- related disease, but IgG4-positive cells are found in a wide variety of inflammatory infiltrates, and the detection of substantial numbers of IgG4- positive plasma cells is therefore not diagnostic of IgG4-related disease.
Tissues from patients with IgG4-related disease show diffuse infiltrates of IgG4-bearing plasma cells, in contrast to the focal aggregates of IgG4-bearing cells that are detected in most other inflammatory mimickers of this condition. A diffuse plasma-cell infiltrate with more than 30 IgG4-positive cells per high power field and a ratio of IgG4 to IgG that is higher than 50% provides compelling evidence of IgG4-related disease.
The study will examine the clinical data from the computerized database of Meir Hospital for patient with unknown IGG4-related disease with high serum levels of IGG4 that were admitted for hospitalization for any reason in a period of 14 years, from January 2000 to June 2014.
Since biopsy has proven to be the hallmark in diagnosing IGG4 RD, we decided to complete the investigation in a pool of patients to whom high IGG4 serum levels where confirmed and to whom biopsies from any suitable tissue where obtained for other reasons than IGG4 RD and then to perform specific staining for IGG4 to those samples, by sending them back to the pathology service at our hospital.
Furthermore clinical and other laboratory features of each positive patient will then be correlated from the history of admission of each patient.
- Conditions
- Undiagnosed IgG4 Related Diseases
- Keywords
- Immunoglobulin G, focus, study, detect, patients
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| IgG4 UKN diagnosis | who ever been found with IgG4 sub class in blood sample or in his byposy |
What is being measured
The primary outcome is the main question the study is designed to answer.
serum level of IGG4
Taken from a computerized database
Measured: 6 months
Secondary outcomes (1)
specific staining for IGG4 to biopsy samples
took from biposy that save for clinical trails
Measured: six months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2014 (estimated)
- Study startOct 2014
- Primary completionSep 2015
- Study completionSep 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Undiagnosed IgG4 Related DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 11 participants (actual)
Sponsor and investigators
- Lead sponsor
- Meir Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, yair levy, Meir Medical Center
- Investigators
- Yair Levy, MD, Principal investigator, Meir Medical CenterShalabi Khaled, Study chair, Meir Medical CenterEvgeny Edelshtein, MD, Study chair, Meir Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02229448
- Sponsor's protocol ID
- IgG4-RD diagnosis
- Status last verified
- Aug 2014
- First submitted
- 28 Aug 2014
- Last updated
- 17 Nov 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Survey of Patients With Elevated Serum IGG4 With Unknown IGG4-related Disease to Whom Biopsy and Performance of Subsequent Specific Staining for Clinical, Laboratory and Pathologic Correlation.
- ClinicalTrials.gov ID
- NCT02229448
- Acronym / sponsor ID
- IgG4-RD diagnosis
- Conditions
- Undiagnosed IgG4 Related Diseases
- Keywords
- Immunoglobulin G, focus, study, detect, patients
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 11 participants (actual)
- Lead sponsor
- Meir Medical CenterUniversity, hospital or other
- Study start
- Oct 2014 (actual)
- Primary completion
- Sep 2015 (actual)
- Study completion
- Sep 2015 (actual)
- First posted
- 1 Sep 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology comprised of a collection of disorders that share specific pathologic, serologic, and clinical features.
Histopathological analysis of biopsy specimens remains the cornerstone in the diagnosis of IgG4- related disease. Elevated concentrations of IgG4 in tissue and serum are helpful in diagnosing IgG4-related disease, but neither one is a specific diagnostic marker. Correlation with specific histopathological findings is essential, regardless of the serum IgG4 concentration, the number of IgG4-positive plasma cells in tissue, or the ratio of IgG4 to IgG in tissue. Misdiagnoses of IgG4-related disease are increasingly common because of excessive emphasis on moderate elevations of serum IgG4 concentration and overreliance on the finding of IgG4-positive plasma cells in tissue.
Detailed description
IgG4 is a unique antibody in both structure and function. This molecule accounts for less than 5% of the total IgG in healthy persons and is the least abundant IgG subclass. In contrast to IgG1, IgG2, and IgG3, serum IgG4 concentrations among ostensibly healthy people vary by a factor of more than 100 (normal range, 0.01 to 1.4 mg per milliliter), but IgG4 concentrations within individual persons are generally stable.
Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology comprised of a collection of disorders that share specific pathologic, serologic, and clinical features.
These different conditions were previously thought to be unrelated [2-4]. The commonly shared features include tumor-like swelling of involved organs, a lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells, and variable degrees of fibrosis that has a characteristic "storiform" pattern. In addition, elevated serum concentrations of IgG4 are found in 60 to 70 percent of patients with IgG4-RD.
Two major presentations of this condition, which often affects more than one organ, are type 1 autoimmune pancreatitis (IgG4-related pancreatitis) and salivary gland disease; the later may present as salivary gland enlargement or as sclerosing sialadenitis (formerly termed "Mikulicz disease" and Küttner's tumor, respectively). These conditions often resemble Sjögren's syndrome but are pathophysiologically distinct from this disorder. The preferred name for the overall condition is IgG4-related disease.
The presence of IgG4-bearing plasma cells is required for a diagnosis of IgG4- related disease, but IgG4-positive cells are found in a wide variety of inflammatory infiltrates, and the detection of substantial numbers of IgG4- positive plasma cells is therefore not diagnostic of IgG4-related disease.
Tissues from patients with IgG4-related disease show diffuse infiltrates of IgG4-bearing plasma cells, in contrast to the focal aggregates of IgG4-bearing cells that are detected in most other inflammatory mimickers of this condition. A diffuse plasma-cell infiltrate with more than 30 IgG4-positive cells per high power field and a ratio of IgG4 to IgG that is higher than 50% provides compelling evidence of IgG4-related disease.
The study will examine the clinical data from the computerized database of Meir Hospital for patient with unknown IGG4-related disease with high serum levels of IGG4 that were admitted for hospitalization for any reason in a period of 14 years, from January 2000 to June 2014.
Since biopsy has proven to be the hallmark in diagnosing IGG4 RD, we decided to complete the investigation in a pool of patients to whom high IGG4 serum levels where confirmed and to whom biopsies from any suitable tissue where obtained for other reasons than IGG4 RD and then to perform specific staining for IGG4 to those samples, by sending them back to the pathology service at our hospital.
Furthermore clinical and other laboratory features of each positive patient will then be correlated from the history of admission of each patient.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| IgG4 UKN diagnosis | – | –who ever been found with IgG4 sub class in blood sample or in his byposy |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients that where admitted during the period of January 2000 to June 2014 at MEIR HOSPITAL- KFAR SABA from all ages, from all parts of Israel, all races will be included, from both genders.
Key inclusion criteria (3 listed)
- All patients that where admitted during the period of January 2000 to June 2014 at MEIR HOSPITAL KFAR SAVA, with at least one result of a high serum level of IGG4 according to the accepted normal range in our laboratory (more than 100mg/dL) and to whom biopsy of a suitable tissue was obtained for other reasons than IGG4 Related Diseases.
- Both genders will be included.
- Patients of all ages.
Key exclusion criteria (1 listed)
- Patients who have already been diagnosed with IGG4-Related Diseases.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
serum level of IGG4
Time frame: 6 months
Taken from a computerized database
1 secondary outcome
specific staining for IGG4 to biopsy samples
Time frame: six months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2017.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yair Levy, MD principal investigator
Meir Medical Center
Shalabi Khaled study chair
Meir Medical Center
Evgeny Edelshtein, MD study chair
Meir Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Undiagnosed IgG4 Related Diseases, run by Meir Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Nov 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
serum level of IGG4 (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2017.